Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc > UPDATE
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(228)
•••
Comment by Dibah42on Jan 11, 2016 10:49am
90 Views
Post# 24446215

RE:RE:RE:UPDATE

RE:RE:RE:UPDATEIf there were new and better molecular diagnostic tests coming on the market and taking market share away from PCA3 then I would concede a beginning of obsolescence.  But the decline in royalties, at least according to YF, were mostly of European provenence and were a reflection of the general economic malaise and the inability of the insurers to come to a consensus regarding reimbursements.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities